WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), announced today that it has been named in BINJE’s BEST Health Care 2025: Companies, Organizations and Service Providers. BINJE, a media outlet covering business and politics across New Jersey, highlighted Tevogen Bio’s Founder and CEO, Ryan Saadi, MD, MPH, for his commitment to health equity and innovation in sustainable biopharma. In its recognition, BINJE noted, “Driven by an unrelenting ...

WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), announced today that it has been named in BINJE’s BEST Health Care 2025: Companies, Organizations and Service Providers. BINJE, a media outlet covering business and politics across New Jersey, highlighted Tevogen Bio’s Founder and CEO, Ryan Saadi, MD, MPH, for his commitment to health equity and innovation in sustainable biopharma. In its recognition, BINJE noted, “Driven by an unrelenting ...

Core Insights - Tevogen Bio Holdings Inc. reported a significant increase in institutional ownership of its common stock, with a 60% rise as of March 31, 2025, compared to December 31, 2024 [2] - Major contributors to this growth were Vanguard and BlackRock, which collectively increased their holdings by 151% [2] - A notable 73% of the 51 institutional investment managers holding Tevogen stock either increased or maintained their positions, indicating a strong influx of new investors [2][3] Company Developments - The increase in institutional ownership is viewed as a positive indicator of confidence in the company's fundamentals and long-term growth potential [3] - Tevogen is advancing its Tevogen.AI initiatives, including new patent activities and collaborations with Microsoft and Databricks, which are aimed at developing targeted therapies for cancers and infectious diseases [3] - The company plans to establish its own GMP cell manufacturing facility, further supporting its growth trajectory [3] Future Outlook - Tevogen will provide another update on institutional ownership following the next SEC reporting period, indicating ongoing transparency and engagement with investors [3]

Core Insights - Tevogen Bio Holdings Inc. reported a 60% increase in institutional ownership of its common stock as of March 31, 2025, compared to December 31, 2024 [2] - Vanguard and BlackRock were the largest contributors to this growth, increasing their holdings by 151% [2] - 73% of the 51 institutional investment managers holding Tevogen stock either increased or maintained their positions, indicating a significant influx of new investors [2][3] Company Developments - The increase in institutional ownership is viewed as a sign of confidence in Tevogen's fundamentals and long-term growth potential [3] - Tevogen is advancing its Tevogen.AI initiatives, including new patent activity and collaborations with Microsoft and Databricks [3] - The company plans to establish its own GMP cell manufacturing facility, which is expected to enhance its capabilities in developing targeted therapies for cancers and infectious diseases [3] Future Outlook - Tevogen will provide another update on institutional ownership following the next SEC reporting period, indicating ongoing monitoring of investor sentiment [3]

Core Viewpoint - Tevogen Bio Holdings Inc. is set to receive $1 million in grant funding to enhance its artificial intelligence-driven drug discovery program, Tevogen.AI, as part of a larger grant agreement potentially totaling $10 million [1][2][6]. Funding Details - The new $1 million funding is part of a previously announced grant agreement with KRHP LLC, which includes an initial $2 million received in January 2025 and may allow for an additional $8 million [2][6]. - The total potential funding of $10 million is categorized as non-dilutive, meaning it will not dilute existing shareholders' equity [2][6]. Strategic Focus - The funding will be directed towards improving Tevogen.AI's capabilities, specifically in target discovery, development timelines, and treatment accessibility for large patient populations [2][3]. - The company emphasizes its commitment to operational efficiency and strategic fund deployment to maximize shareholder value and patient impact [3]. Leadership Statement - Dr. Ryan Saadi, Chairman and CEO of Tevogen, highlighted the grant as an endorsement of Tevogen.AI's potential to accelerate drug development, reduce costs, and enhance access to precision cell therapies [3].

Core Viewpoint - Tevogen Bio Holdings Inc. is expanding its AI-driven platform, Tevogen.AI, to enhance patient data integration for clinical trial participant identification, aiming to accelerate the development of personalized T cell therapies [1][2][3] Group 1: Tevogen.AI and PredicTcell™ - Tevogen.AI, supported by Microsoft and Databricks, will analyze electronic health records and real-world patient data to identify potential clinical trial participants [2] - The integration of patient data with the PredicTcell™ model is expected to enhance the ExacTcell™ pipeline development [2][3] Group 2: Clinical Trial Efficiency - Tevogen.AI aims to improve clinical trial efficiency, scalability, and inclusivity by rapidly identifying and enrolling suitable patients [3] - The initiative is designed to address critical bottlenecks in clinical development, potentially accelerating time-to-market for new therapeutic interventions [3][6] Group 3: Strategic Goals - The company’s mission focuses on achieving commercially attractive, economically viable, and cost-effective personalized T cell therapies [3] - By enhancing patient outcomes and expediting therapeutic approvals, Tevogen.AI seeks to provide a foundation for commercial success and investment growth [3]

Company Overview - Tevogen Bio Holdings Inc. has officially opened its newly expanded corporate headquarters in Warren, New Jersey, which was fully funded by the CEO, Ryan Saadi, resulting in no costs to the company or its shareholders [2][6]. Facility Expansion - The new facility has been completed ahead of schedule and more than doubles the previous footprint of Tevogen, allowing for the centralization of research, regulatory affairs, and the expanding Tevogen.AI teams under one roof [3][6]. Future Plans - A formal ribbon-cutting ceremony is planned to celebrate the new headquarters, which will include local officials, employees, and community partners [3].

Core Insights - Tevogen Bio Holdings Inc. is advancing its artificial intelligence initiative, Tevogen.AI™, to enhance its immunotherapy development pipeline and reduce costs [1][2] Group 1: Tevogen.AI Initiative - Tevogen.AI aims to integrate machine learning and predictive modeling with ExacTcell™ technology to improve target identification and pre-clinical processes [2] - The initiative includes two proprietary technologies with patents pending, and the company plans to expand its AI applications beyond its current scope [3] Group 2: Strategic Partnerships - Tevogen has partnered with Microsoft for AI expertise and cloud infrastructure, and with Databricks for data engineering and analytics to enhance predictive accuracy [5] Group 3: Proprietary Technologies - PredicTcell™ utilizes AI to predict immunologically active peptide complexes, improving precision in immunotherapy treatments [6] - AdapTcell™ focuses on decoding interactions between human leukocyte antigens and T cells, enhancing understanding of immune responses [8][9] Group 4: Future Plans - Tevogen.AI plans to utilize its platforms for clinical trial patient identification, aiming for efficiency and cost reduction in drug development [10]

Core Insights - Tevogen Bio Holdings Inc. is preparing to provide updates to stockholders ahead of its Annual Meeting scheduled for June 23, 2025, focusing on its innovative business model and strategic growth initiatives [1] Group 1: Portfolio Assets - The company will update investors on its portfolio assets, which include Tevogen Bio Oncology, Tevogen Bio Specialty Care, and Tevogen.AI, valued at over $10 billion as of October 2024 [2] Group 2: Corporate Highlights - Tevogen will detail two strategic initiatives: Tevogen.AI and Tevogen Generics & Biosimilars, alongside plans to expand its operational footprint with an upgraded headquarters [3] Group 3: Financial Market Dynamics - Management is monitoring stock dynamics, noting the impact of a limited tradable float and the growing institutional ownership, which reflects strong investor confidence and long-term holding patterns [4]

Core Insights - Tevogen Bio Holdings Inc. is focused on advancing patient-centric solutions through immunotherapy and artificial intelligence, with a commitment to developing off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers [1] - The company emphasizes the significant insider ownership, with approximately 74% of outstanding shares held by executive officers and board members, indicating strong confidence in the company's mission and progress [2][3] Company Overview - Tevogen's clinical-stage immunotherapy, Tevogen Bio, aims to create innovative treatments for infectious diseases and cancers [1] - The artificial intelligence initiative, Tevogen.AI, is designed to enhance drug discovery, clinical trial efficiency, and patient access [1] Insider Ownership - The high level of insider ownership (74%) is noted as a unique advantage compared to other companies in the industry, with insiders primarily selling shares only to meet tax obligations [2] - CEO Dr. Ryan Saadi highlighted the collective confidence of insiders in the company's progress and potential, especially in the context of current market volatility [3] Market Position - Tevogen operates solely in the U.S. and is described as being tariff-insensitive, which may provide a competitive edge in the current economic climate [3]